PTGFRN promotes non-small cell lung cancer malignant progression and reprograms BCAA metabolism by activating STAT3/BCAT1 pathway
Authors:
- 21 October 2025
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 4) , 117445
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Post-translational modifications of Stat3: The state of the artCellular Signalling, 2025
- The effects of STAT3 acetylation on the transcriptional activity and tumorigenesisBiochemical Pharmacology, 2025
- STAT3 Signaling Pathway in Health and DiseaseMedcomm, 2025
- Update 2025: Management of Non‑Small-Cell Lung CancerLung, 2025
- Prostaglandin F2 Receptor Negative Regulator (PTGFRN) Expression Correlates With a Metastatic‐like Phenotype in Epidermoid Carcinoma, Pediatric Medulloblastoma, and MesotheliomaJournal of Cellular Biochemistry, 2024
- APC/C CDH1 ubiquitinates STAT3 in mitosisThe International Journal of Biochemistry & Cell Biology, 2022
- BCAT1 redox function maintains mitotic fidelityCell Reports, 2022
- The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiformeCancer Letters, 2019
- Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase InhibitorsCell Reports, 2019
- In situ chemical cross-linking on living cells reveals CD9P-1 cis-oligomer at cell surfaceJournal of Proteomics, 2009